Hay Fever Clinical Trial
Official title:
Observational Study With PASCALLERG ® in Patients With Hay Fever
The aim of this observational study is to document the therapeutic use of PASCALLERG ® for hay fever. Based on the survey is a decrease in disease-specific symptoms when taking PASCALLERG ® over a period of 4 weeks will be documented. In addition to the compatibility can be assessed.
There are documented male and female patients over the age of one year who suffer from hay fever. The traetment time is about a period of 4 weeks with PASCALLERG® tablets. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00658918 -
To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)
|
Phase 3 | |
| Recruiting |
NCT05960266 -
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
|
Early Phase 1 | |
| Completed |
NCT00574210 -
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
|
Phase 2 | |
| Completed |
NCT00384475 -
A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)
|
Phase 3 | |
| Completed |
NCT01506375 -
Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant
|
Phase 2 | |
| Completed |
NCT01137357 -
Probiotics for Reduction Of Markers In Subjects With Allergy
|
N/A | |
| Completed |
NCT00261287 -
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
|
Phase 3 | |
| Completed |
NCT00659594 -
Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)
|
Phase 3 | |
| Active, not recruiting |
NCT00247520 -
Safety and Efficacy Study of rEV131 in Allergic Rhinitis
|
Phase 1/Phase 2 | |
| Completed |
NCT00163514 -
Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)
|
Phase 3 | |
| Completed |
NCT04326309 -
Audio Data Collection for Identification and Classification of Coughing
|
||
| Completed |
NCT00305487 -
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
|
Phase 3 | |
| Completed |
NCT02932774 -
Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)
|
Phase 4 | |
| Completed |
NCT00163488 -
Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)
|
Phase 3 | |
| Not yet recruiting |
NCT03724240 -
Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
|
Phase 3 | |
| Completed |
NCT02619331 -
Evaluation of High Speed Laser Doppler Imaging Technology
|
N/A | |
| Completed |
NCT00659503 -
Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)
|
Phase 3 | |
| Completed |
NCT01024608 -
Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
|
Phase 3 | |
| Completed |
NCT02560948 -
Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
|
Phase 3 | |
| Completed |
NCT01308021 -
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
|
Phase 2 |